Keynote Address Speaker and Panel Updates Announced
Reporter: Aviva Lev-Ari, PhD, RN
Scientific innovation is at the core of Big Pharma‘s business model, but continuous transformation critical to R&D momentum has been an ongoing, multi-year challenge. Big Pharma has struggled to manage costs while delivering on productivity. Unmet medical need remains a compelling scientific and business opportunity, as is development of truly differentiated medicines and orphan drugs.
R&D: Balancing Austerity and Innovation at the 23rd Annual PSA: The Pharmaceutical Strategy Conference, being held September 23-25, 2013 at the Millennium Broadway Hotel in New York City. Successful R&D leaders discuss their strategies for maintaining excellence and adaptability in the face of internal and external hurdles.
Matthias Evers, PhD (Moderator), Partner, McKinsey & Company
George Yancopoulos, MD, PhD, President & CSO, Regeneron Pharmaceuticals
Rupert Vessey, SVP, R&D Strategy, Merck & Co., Inc.
JC Gutierrez-Ramos, SVP & Head of Biotherapeutics R&D, Pfizer
Keynote Address: Applying the Lessons of Philanthropy
Tadataka “Tachi” Yamada
Chief Medical and Scientific Officer